MX353352B - Anticuerpos anti-cd100 y metodos para su uso. - Google Patents

Anticuerpos anti-cd100 y metodos para su uso.

Info

Publication number
MX353352B
MX353352B MX2014010424A MX2014010424A MX353352B MX 353352 B MX353352 B MX 353352B MX 2014010424 A MX2014010424 A MX 2014010424A MX 2014010424 A MX2014010424 A MX 2014010424A MX 353352 B MX353352 B MX 353352B
Authority
MX
Mexico
Prior art keywords
methods
antibodies
same
diseases
neutralize
Prior art date
Application number
MX2014010424A
Other languages
English (en)
Inventor
S Smith Ernest
Lee Fisher Terrence
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of MX353352B publication Critical patent/MX353352B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0001—Archaeal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para tratar enfermedades asociadas con CD100, incluyendo ciertas enfermedades autoinmunitarias, enfermedades inflamatorias, y canceres. En particular, se han desarrollado los anticuerpos anti-CD100 para neutralizar CD100.
MX2014010424A 2009-05-08 2010-05-07 Anticuerpos anti-cd100 y metodos para su uso. MX353352B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17682609P 2009-05-08 2009-05-08
US32521310P 2010-04-16 2010-04-16
PCT/US2010/034116 WO2010129917A2 (en) 2009-05-08 2010-05-07 Anti-cd100 antibodies and methods for using the same

Publications (1)

Publication Number Publication Date
MX353352B true MX353352B (es) 2018-01-10

Family

ID=43050912

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011011718A MX2011011718A (es) 2009-05-08 2010-05-07 Anticuerpos anti-cd100 y metodos para su uso.
MX2014010424A MX353352B (es) 2009-05-08 2010-05-07 Anticuerpos anti-cd100 y metodos para su uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011011718A MX2011011718A (es) 2009-05-08 2010-05-07 Anticuerpos anti-cd100 y metodos para su uso.

Country Status (19)

Country Link
US (6) US8496938B2 (es)
EP (2) EP2427212B1 (es)
JP (3) JP6059013B2 (es)
KR (2) KR101754433B1 (es)
CN (2) CN108912228B (es)
AU (2) AU2010245668B2 (es)
CA (1) CA2760890C (es)
DK (1) DK2427212T3 (es)
EA (1) EA025245B1 (es)
ES (1) ES2647823T3 (es)
IL (3) IL216002A (es)
MX (2) MX2011011718A (es)
NO (1) NO2427212T3 (es)
NZ (2) NZ618067A (es)
PL (1) PL2427212T3 (es)
PT (1) PT2427212T (es)
SG (1) SG175417A1 (es)
WO (1) WO2010129917A2 (es)
ZA (1) ZA201108162B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101754433B1 (ko) 2009-05-08 2017-07-05 백시넥스 인코포레이티드 항-ｃｄ100 항체 및 이의 사용 방법
EP2487242A1 (en) * 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
EP2711023B1 (en) 2011-05-13 2017-07-12 National University Corporation Tokyo Medical and Dental University Osteogenesis promoter
ES2669209T3 (es) * 2011-10-11 2018-05-24 Vaccinex, Inc. Uso de moléculas de unión a semaforina-4D para la modulación de la permeabilidad de la barrera hematoencefálica
US8790652B2 (en) * 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
AT512165B1 (de) * 2011-12-27 2013-06-15 Blum Gmbh Julius Antriebsvorrichtung für ein bewegbares möbelteil
US9090709B2 (en) * 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) * 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
WO2014116982A2 (en) * 2013-01-25 2014-07-31 Brandeis University Methods of modulating gabaergic inhibitory synapse formation and function
MX2015013288A (es) 2013-03-18 2016-04-07 Biocerox Prod Bv Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos.
EP3656392A1 (en) * 2013-06-25 2020-05-27 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) * 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
AU2017252427B2 (en) 2016-04-22 2023-07-13 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
EP3494131B1 (en) 2016-08-02 2024-09-18 Vaccinex, Inc. Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
JP2019536471A (ja) 2016-09-27 2019-12-19 セロ・セラピューティクス・インコーポレイテッドＣＥＲＯ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． キメラエンガルフメント受容体分子
CA3053649A1 (en) 2017-03-20 2018-09-27 Vaccinex, Inc. Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
EP3600421A4 (en) * 2017-03-23 2021-01-06 The Trustees of The University of Pennsylvania ANTI-C5A ANTIBODIES AND USES THEREOF
SG11201909466RA (en) * 2017-05-05 2019-11-28 Vaccinex Inc Human anti-semaphorin 4d antibody
AU2018341244A1 (en) 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
WO2019191332A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
CN110713537B (zh) * 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
CN109125731B (zh) * 2018-10-22 2019-10-25 华中科技大学同济医学院附属协和医院 Sema4D/PlexinB1抑制剂在制备治疗及预防眼底血管疾病药物中的应用
MX2021011799A (es) 2019-03-28 2021-10-26 Vaccinex Inc Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
CA3142777A1 (en) 2019-06-21 2020-12-24 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
CN114341170B (zh) * 2019-07-19 2023-09-01 神州细胞工程有限公司 一种人源化抗vegfr2抗体及其应用
AU2020322474A1 (en) 2019-08-01 2022-03-10 Vaccinex,Inc. Combined inhibition of semaphorin-4D and TGFβ and compositions therefor
AU2021297152A1 (en) 2020-06-25 2023-02-02 The Sydney Children's Hospitals Network Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
CN113583122B (zh) * 2021-07-29 2023-08-29 武汉华美生物工程有限公司 抗人sema4d抗体及其制备方法和应用
AU2021465518A1 (en) 2021-09-27 2024-05-02 Vaccinex, Inc. Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
CN118510806A (zh) * 2021-11-03 2024-08-16 罗特格斯新泽西州立大学 抗受体酪氨酸激酶EphA5的抗体-药物缀合物
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
CN117866091A (zh) * 2022-10-12 2024-04-12 三优生物医药(上海)有限公司 抗cd100抗体及其用途
CN118108841A (zh) * 2022-11-30 2024-05-31 三优生物医药(上海)有限公司 抗cd100抗体及其用途

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
EP1149913A1 (en) 1990-11-09 2001-10-31 GILLIES, Stephen D. Cytokine immunoconjugates
WO1992019973A1 (en) 1991-04-26 1992-11-12 Surface Active Limited Novel antibodies, and methods for their use
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
DK0678523T3 (da) * 1993-01-14 2005-01-10 Chemo Sero Therapeut Res Inst Rekombinant anti-HIV antistof og fremstilling deraf
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DK0973804T3 (da) 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF-antistoffer
EP0973916A1 (en) 1997-04-11 2000-01-26 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
WO2000028016A1 (en) 1998-11-10 2000-05-18 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
US7468277B2 (en) 1999-12-23 2008-12-23 Cornell Research Foundation, Inc. Enriched preparation of human fetal multipotential neural stem cells
CN1329060A (zh) * 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人semaphorin蛋白9和编码这种多肽的多核苷酸
WO2002102855A2 (en) 2000-11-17 2002-12-27 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP1423428B2 (en) 2001-06-20 2012-11-14 Fibron Ltd. Antibodies that block fgfr3 activation, methods of screening for and uses thereof
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
ITTO20010128U1 (it) 2001-07-25 2003-01-25 Aris Spa Struttura ausiliaria particolarmente per l'incremento della capacita'di trasporto dei veicoli cingolati polivalenti tipo m 113 e derivati.
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
US7351803B2 (en) * 2002-05-30 2008-04-01 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
JP4792392B2 (ja) * 2003-09-11 2011-10-12 コーナーストーン セラピューティクス インコーポレイテッド Ｈｍｇｂ１に対するモノクローナル抗体
NZ547591A (en) 2003-12-04 2009-11-27 Vaccinex Inc Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
RU2398777C2 (ru) 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
US7919246B2 (en) * 2005-04-07 2011-04-05 Novartis Vaccines And Diagnostics, Inc. SEMA4D in cancer diagnosis, detection and treatment
EP1952147A2 (en) * 2005-11-16 2008-08-06 Novartis AG Biomarkers for anti-nogo-a antibody treatment in spinal cord injury
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
US7657639B2 (en) * 2006-07-21 2010-02-02 International Business Machines Corporation Method and system for identity provider migration using federated single-sign-on operation
US8257706B2 (en) * 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
WO2008100995A1 (en) * 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
CA2678618C (en) 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cd1d molecules
CN101932333A (zh) 2007-12-26 2010-12-29 瓦西尼斯公司 抗c35抗体联合疗法和方法
PE20091378A1 (es) 2008-01-10 2009-10-14 Genentech Inc Polipeptidos agonistas plexind1
KR101754433B1 (ko) 2009-05-08 2017-07-05 백시넥스 인코포레이티드 항-ｃｄ100 항체 및 이의 사용 방법
WO2010132867A1 (en) 2009-05-15 2010-11-18 Irx Therapeutics, Inc. Vaccine immunotherapy
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
CN103347896B (zh) 2010-09-02 2017-06-13 瓦西尼斯公司 抗cxcl13抗体和其使用方法
EP2711023B1 (en) 2011-05-13 2017-07-12 National University Corporation Tokyo Medical and Dental University Osteogenesis promoter
CA2851244A1 (en) 2011-10-06 2013-04-11 The Board Of Regents, The University Of Texas System Anti-human sema4a antibodies useful to treat disease
ES2669209T3 (es) 2011-10-11 2018-05-24 Vaccinex, Inc. Uso de moléculas de unión a semaforina-4D para la modulación de la permeabilidad de la barrera hematoencefálica
US8790652B2 (en) * 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
NZ629828A (en) 2012-03-02 2017-05-26 Vaccinex Inc Methods for the treatment of b cell-mediated inflammatory diseases
US9375282B2 (en) 2012-03-26 2016-06-28 Covidien Lp Light energy sealing, cutting and sensing surgical device
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
CA2899344C (en) 2013-01-31 2022-11-08 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
EP3656392A1 (en) 2013-06-25 2020-05-27 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
AU2017252427B2 (en) 2016-04-22 2023-07-13 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
EP3494131B1 (en) 2016-08-02 2024-09-18 Vaccinex, Inc. Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
CN110325213A (zh) 2017-02-22 2019-10-11 瓦西尼斯公司 神经退行性或神经炎性疾病中胶质细胞活化的早期检测

Also Published As

Publication number Publication date
PL2427212T3 (pl) 2018-02-28
CN102458468B (zh) 2018-05-18
CA2760890C (en) 2019-08-20
US20140072578A1 (en) 2014-03-13
JP6096946B2 (ja) 2017-03-15
ZA201108162B (en) 2012-07-25
NZ618067A (en) 2015-07-31
DK2427212T3 (en) 2017-12-04
KR20120044300A (ko) 2012-05-07
US8816058B2 (en) 2014-08-26
US20120270268A1 (en) 2012-10-25
CN108912228A (zh) 2018-11-30
EA201171374A1 (ru) 2012-06-29
KR101754433B1 (ko) 2017-07-05
AU2016247068A1 (en) 2016-11-03
NZ596136A (en) 2013-12-20
US12006364B2 (en) 2024-06-11
US9605055B2 (en) 2017-03-28
US20130274449A1 (en) 2013-10-17
US20170306017A1 (en) 2017-10-26
US11274149B2 (en) 2022-03-15
US20100285036A1 (en) 2010-11-11
EP2427212A4 (en) 2012-11-14
IL216002A (en) 2016-07-31
CN102458468A (zh) 2012-05-16
MX2011011718A (es) 2012-01-27
PT2427212T (pt) 2017-11-20
EA025245B1 (ru) 2016-12-30
JP2016128474A (ja) 2016-07-14
IL261348A (en) 2018-10-31
JP2012525854A (ja) 2012-10-25
SG175417A1 (en) 2011-12-29
US20220185884A1 (en) 2022-06-16
US8496938B2 (en) 2013-07-30
EP2427212A2 (en) 2012-03-14
JP2017113017A (ja) 2017-06-29
NO2427212T3 (es) 2018-01-20
WO2010129917A2 (en) 2010-11-11
ES2647823T3 (es) 2017-12-26
US9676840B2 (en) 2017-06-13
IL244197A0 (en) 2016-04-21
IL216002A0 (en) 2012-01-31
AU2010245668A1 (en) 2011-11-24
WO2010129917A3 (en) 2011-01-06
CN108912228B (zh) 2022-03-15
EP3320920A1 (en) 2018-05-16
CA2760890A1 (en) 2010-11-11
AU2010245668B2 (en) 2016-07-14
EP2427212B1 (en) 2017-08-23
JP6059013B2 (ja) 2017-01-11
KR20170080705A (ko) 2017-07-10

Similar Documents

Publication Publication Date Title
MX353352B (es) Anticuerpos anti-cd100 y metodos para su uso.
MX353476B (es) Anticuerpos anti-cxcl13 y metodos para usarlos.
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
MX362039B (es) Anticuerpos anti-il-23.
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
PH12014501108A1 (en) Anti-il-36r antibodies
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
WO2013006490A3 (en) Antibodies that specifically bind to tim3
MX339239B (es) Anticuerpos anti-cd40 y metodos de uso.
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
IN2012DN00863A (es)
EP2614085A4 (en) ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE
IN2012DN02046A (es)
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
MX2015015232A (es) Anticuerpo monoclonal dirigido contra cxcr5.
AR123070A2 (es) Anticuerpos anti-il-23
TN2013000186A1 (en) Anti-il-23 antibodies
TN2014000207A1 (en) Anti il-36r antibodies